Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...
Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...
Another long-term casualty of the state/local funding cuts will likely be recruiting, training, and retaining the expert ...
An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any metastases with durvalumab vs placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback